Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.44 |
| ▸ | CTSD | P07339 | 10/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894446 | 1.00 | BACE1 (0.44) | BACE1CTSDRAF1BRAFBACE2 | |
| SCHEMBL11894662 | 0.88 | BACE1 (0.38) | BACE1RAF1BRAFBACE2KCNH2 | |
| SCHEMBL11894660 | 0.88 | BACE1 (0.38) | BACE1RAF1BRAFBACE2KCNH2 | |
| SCHEMBL11894520 | 0.83 | BACE1 (0.44) | BACE1CTSDRAF1BRAFBACE2 | |
| SCHEMBL14768339 | 0.82 | BACE1 (0.48) | BACE1KCNH2 | |
| SCHEMBL14768340 | 0.82 | BACE1 (0.48) | BACE1KCNH2 | |
| SCHEMBL11894363 | 0.80 | BACE1 (0.47) | BACE1 | |
| SCHEMBL362220 | 0.80 | BACE1 (0.46) | BACE1 | |
| SCHEMBL363017 | 0.80 | BACE1 (0.47) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL11894192 | 0.77 | BACE1 (0.57) | BACE1CTSDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885CTSD 337/4885RAF1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.